| Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. | |
| | |
MedLine Citation:
|
PMID: 20164558 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To determine the additional value of cerebrospinal fluid (CSF)amyloid-beta1-40 (Abeta40) next to amyloid-beta1-42 (beta42), total tau (Tau), and tau phosphorylated at threonine-181 (pTau) to distinguish patients with frontotemporal lobar degeneration (FTLD), Alzheimer's disease (AD), and controls, we measured CSF levels of Abeta40, Abeta42, pTau, and Tau in 55 patients with FTLD, 60 with AD, and 40 control subjects. Logistic regression was used to identify biomarkers that best distinguished the groups. Additionally, a decision tree (cost=test method; Matlab 7.7) was used to predict diagnosis selecting the best set of biomarkers with the optimal cut-off. Logistic regression showed that Abeta42 and pTau CSF levels provided optimal distinction between AD and FTLD. A combination of Abeta42, Tau, and Abeta40 optimally discriminated FTLD from controls and AD from controls. The decision tree used Abeta42 (cut-off 578 pg/ml) to identify AD (positive predictive value (PPV) 97%), followed by Tau(cut-off 336 pg/ml) to identify FTLD (PPV 67%), and in the last step,Abeta40 (cut-off 10 ng/ml) was used to differentiate controls (PPV68%). Applying CSF Abeta40 levels in the model, the PPV of diagnosis increased to 75% as opposed to 70% when only Abeta42 and Tau were used. CSF Abeta40 levels added to the conventional CSF biomarkers increases the potential to discriminate subjects with dementia from controls. Our findings favor the implementation of CSF Abeta40 in differential diagnosis between FTLD, AD, and control subjects. |
| | |
Authors:
|
Nicolaas A Verwey; Maartje I Kester; Wiesje M van der Flier; Robert Veerhuis; Hans Berkhof; Harry Twaalfhoven; Marinus A Blankenstein; Philip Scheltens And; Yolande A L Pijnenburg |
Related Documents
:
|
2333358 - Csf diazepam-binding inhibitor in alcoholics and normal controls. 2196148 - Extravascular penetration of ciprofloxacin. a review. 22156488 - Association between increased serum osteoprotegerin levels and improvement in bone mine... 18997298 - Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with ea... 16800768 - Intact anthocyanins and metabolites in rat urine and plasma after 3 months of anthocyan... 581498 - Bioavailability of sulfadiazine solutions, suspensions, and tablets in humans. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of Alzheimer's disease : JAD Volume: 20 ISSN: 1875-8908 ISO Abbreviation: J. Alzheimers Dis. Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-05-27 Completed Date: 2010-09-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9814863 Medline TA: J Alzheimers Dis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 445-52 Citation Subset: IM |
Affiliation:
|
Department of Neurology, VU University Medical Center, Alzheimer Center Amsterdam, The Netherlands. n.verwey@vumc.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Alzheimer Disease / cerebrospinal fluid Amyloid beta-Protein / cerebrospinal fluid* Analysis of Variance Enzyme-Linked Immunosorbent Assay / methods Female Follow-Up Studies Frontotemporal Lobar Degeneration / cerebrospinal fluid* Humans Logistic Models Male Middle Aged Peptide Fragments / cerebrospinal fluid* Retrospective Studies tau Proteins / cerebrospinal fluid |
| Chemical | |
Reg. No./Substance:
|
0/Amyloid beta-Protein; 0/Peptide Fragments; 0/amyloid beta-protein (1-40); 0/amyloid beta-protein (1-42); 0/tau Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Meditation Effects on Cognitive Function and Cerebral Blood Flow In Subjects with Memory Loss: A Pre...
Next Document: Diagnostic Utility of Novel MRI-Based Biomarkers for Alzheimer's Disease: Diffusion Tensor Imaging a...